Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
Extended Release Naltrexone for Opioid-Dependent Youth
- Conditions
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Friends Research Institute, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT01843023
- Locations
- 🇺🇸
Friends Research Institute, Baltimore, Maryland, United States
🇺🇸Mountain Manor Treatment Center, Baltimore, Maryland, United States
An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Mundipharma Korea Ltd
- Target Recruit Count
- 245
- Registration Number
- NCT01818700
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
- Conditions
- Interventions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2015-12-24
- Target Recruit Count
- 518
- Registration Number
- NCT01809106
- Locations
- 🇮🇹
Multimedica, Sesto San Giovanni, Italy
🇮🇹Istituto Scientifico San Raffaele, Milano, Italy
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera, Reggio Emilia, RE, Italy
Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT01738503
- Locations
- 🇺🇸
Vince and Associates Clinical Research, Overland Park, Kansas, United States
Neurocognitive Effects of Opiate Agonist Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Albert Einstein College of Medicine
- Target Recruit Count
- 135
- Registration Number
- NCT01733693
- Locations
- 🇺🇸
Albert Einstein College of Medicine of Yeshiva University, Bronx, New York, United States
🇺🇸Fordham University, Bronx, New York, United States
Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin
- Conditions
- Interventions
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 1
- Registration Number
- NCT01723527
- Locations
- 🇺🇸
Center for Learning and Health, Baltimore, Maryland, United States
Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Pediatrix
- Target Recruit Count
- 29
- Registration Number
- NCT01708707
- Locations
- 🇺🇸
Banner - University Medical Center Phoenix, Phoenix, Arizona, United States
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- BioDelivery Sciences International
- Target Recruit Count
- 815
- Registration Number
- NCT01675167
- Locations
- 🇺🇸
Horizon Research Group. Inc / Alabama Orthopedice, Mobile, Alabama, United States
🇺🇸FPA Clinical Research, Kissimmee, Florida, United States
🇺🇸Global Research, Anaheim, California, United States
Buprenorphine Disposition and Cyclosporine
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT01648270
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Norspan Transdermal Patches Study in Osteoarthritis Patients
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT01643759
- Locations
- 🇨🇳
Investigational Site: Peking Union Medical Hospital(PUMC), Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.